Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
In a recent small study, resistance was limited to the emtricitabine component of Truvada and did not seem a major cause for concern.
Gilead’s HIV capsid inhibitor might need dosing only every six months
A recent survey found that pharmacies are insufficiently educating the public about unused opioid and antibiotic disposal.
Expanded access study confirms the long-acting monoclonal antibody works well in people with extensive prior treatment.
The attachment inhibitor performed well as an adjunct to an optimized antiretroviral regimen among those with multidrug-resistant HIV.
Researchers attribute the decline in multidrug-resistant virus, which began in 2004, to newer, highly potent antiretrovirals.
Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.
Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.
However, because this combo is not as effective as the current standard treatment, the search for new options continues.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Researchers followed a small group of people with highly drug-resistant virus taking injectable antibody.
This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.